Antimalarial compound identification and design: advances in the patent literature, 2000 – 2003

Bibliography

• WONGSRICHANALAI C, PICKARD AL, WERNSDORFER WH, MESHNICK SR: Epidemiology of drug-resistant malaria. Lancet Infect. Dis. (2002) 2(4):209–218.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG: Plasmodium: drug discovery and development - an industrial perspective. Exp. Parasitol (1997) 87(3):293–304.
   PubMedGoogle Scholar
• WELLEMS TE, PLOWE CV: Chloroquine -resistant malaria.' Infect. Dis. (2001) 184(6):770–776.
   Google Scholar
• MAY J, MEYER CG: Chemoresistance in fakiparum malaria. Trends Parasitol (2003) 19(10):432–435.
   PubMedGoogle Scholar
• BLOLAND PB, ETTLING M, MEEK S: Combination therapy for malaria in Africa: hype or hope? Bull. World Health Organ. (2000) 78(12):1378–1388.
   PubMed Web of Science ®Google Scholar
• DUFFY PE, MUTABINGWA TK: Drug combinations for malaria: time to ACT? Lancet (2004) 363(9402):3–4.
   PubMed Web of Science ®Google Scholar
• TRAGER W, JENSEN JB: Human malaria parasites in continuous culture. Science (1976) 193 (4254):673–675.
   PubMed Web of Science ®Google Scholar
• DESJARDINS RE, CANFIELD CJ, HAYNES JD, CHULAY JD: Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob. Agents Chemother. (1979) 16(6):710–718.
   PubMed Web of Science ®Google Scholar
• AGER AL: Rodent Malaria Model. Springer Verlag (1984).
   Google Scholar
• BORSTNIK K, PAIK IH, SHAPIRO TA, POSNER GH: Antimalarial chemotherapeutic peroxides: artemisinin, yingzhaosu A and related compounds. Int. Parasitol (2002) 32(13):1661–1667.
   PubMed Web of Science ®Google Scholar
• PLOYPRADITH P: Development of artemisinin and its structurally simplified trioxane derivatives as antimalarial drugs. Acta Bop. (2004) 89(3):329–342.
   Google Scholar
• O'NEILL PM, MILLER A, BISHOP LP et al.: Synthesis, antimalarial activity, biomimetic iron(II) chemistry, and in vivo metabolism of novel, potent C-10-phenoxy derivatives of dihydroartemisinin. I Med. Chem. (2001) 44(1):58–68.
   Google Scholar
• HINDLEY S, WARD SA, STORR RC et al.: Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. Med. Chem. (2002) 45(5):1052–1063.
   Google Scholar
• GORDI T, LEPIST El: Artemisinin derivatives: toxic for laboratory animals, safe for humans? Toxicol Lett. (2004) 147(2):99–107.
   Google Scholar
• JEYADEVAN JP, BRAY PG, CHADWICK J et al.: Antimalarial and antitumor evaluation of novel C-10 non-acetal dimers of 101342- hydroxyethyl ) deoxoartemisinin. I Med. Chem. (2004) 47(5):1290–1298.
   PubMedGoogle Scholar
• AVERY MA, MURALEEDHARAN KM, DESAI PV et al.: Structure-activity relationships of the antimalarial agent artemisinin 8. Design, synthesis, and CoMFA studies toward the development of artemisinin-based drugs against leishmaniasis and malaria. j Med. Chem. (2003) 46(20):4244–4258.
   Google Scholar
• POSNER GH, CUMMING JN: WOO SH et al.: Orally active antimalarial 3-substituted trioxanes: new synthetic methodology and biological evaluation. Med . Chem. (1998) 41(6):940–951.
   Google Scholar
• POSNER GH, WANG D, CUMMING JN et al.: Further evidence supporting the importance of and the restrictions on a carbon-centered radical for high antimalarial activity of 1,2,4-trioxaries like artemisinin. Med . Chem. (1995) 38(13):2273–2275.
   Google Scholar
• POSNER GH, JEON HB, PARKER MH et al.: Antimalarial simplified 3-aryltrioxanes: synthesis and preclinical efficacy/toxicity testing in rodents. Med. Chem. (2001) 44(19):3054–3058.
   Google Scholar
• O'NEILL PM, BRAY PG, HAWLEY SR, WARD SA, PARK BK: 4-Aminoquinolines-past, present, and future: a chemical perspective. Pharmacol Ther. (1998) 77(1):29–58.
   PubMed Web of Science ®Google Scholar
• SMRKOVSKI LL, BUCK RL, ALCANTARA AK, RODRIGUEZ CS, UYLANGCO CV: Studies of resistance to chloroquine, quinine, amodiaquine and mefloquine among Philippine strains of Plasmodium fakiparum. Trans. R. Soc. Bop. Med. Hyg. (1985) 79(1):37–41.
   PubMed Web of Science ®Google Scholar
• O'NEILL PM, MUKHTAR A, STOCKS PA et al.: Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. I Med. Chem. (2003) 46(23):4933–4945.
   Google Scholar
• LE HESRAN JY, BOUDIN C, COT M et al.: ha vivo resistance of Plasmodium falciparum to chloroquine and amodiaquine in south Cameroon and age-related efficacy of the drugs. Ann. Bop. Med. Thrash& (1997) 91(6):661–664.
   Google Scholar
• OLLIARO P, NEVILL C, LEBRAS J et al.: Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet (1996) 348(9036):1196–1201.
   PubMed Web of Science ®Google Scholar
• LIND DE, LEVI JA, VINCENT PC: Amodiaquine-induced agranulocytosis: toxic effect of amodiaquine in bone marrow cultures in vitro. Br. Med. (1973) 1(5851):458–460.
   PubMedGoogle Scholar
• NEFTEL KA: WOODTLY W, SCHMID M, FRICK PG, FEHR J: Amodiaquine induced agranulocytosis and liver damage. Br. Med. j (Clin. Res. Ed.) (1986) 292(6522):721–723.
   PubMed Web of Science ®Google Scholar
• WARD SA, BRAY PG: Is reversal of chloroquine resistance ready for the clinic? Lancet (2001) 357(9260):904.
   PubMedGoogle Scholar
• CRANDALL I, CHARUK J, KAIN KC: Nonylphenolethoxylates as malarial chloroquine resistance reversal agents. Antimicrob. Agents Chemother. (2000) 44(9):2431–2434.
   PubMedGoogle Scholar
• CIACH M, ZONG K, KAIN KC, CRANDALL I: Reversal of mefloquine and quinine resistance in Plasmodium fakiparum with NP30. Antimicrob. Agents Chemother. (2003) 47(8):2393–2396.
   PubMedGoogle Scholar
• BAIRD JK, FRYAUFF DJ, HOFFMAN SL: Primaquine for prevention of malaria in travelers. Chia. Infect. Dis. (2003) 37(12):1659–1667.
   PubMedGoogle Scholar
• LING J, BAIRD JK, FRYAUFF DJ et a/.: Randomized, placebo-controlled trial of atovaquone/proguanil for the prevention of Plasmodium fakiparum or Plasmodium vivax malaria among migrants to Papua, Indonesia. Chia. Infect. Dis. (2002) 35(7):825–833.
   Google Scholar
• LAL J, MEHROTRA N, GUPTA RC: Analysis and pharmacokinetics of bulaquine and its major metabolite primaquine in rabbits using an LC-UV method-a pilot study. .1. Pharm. Biomed. Anal. (2003) 32(1):141–150.
   Google Scholar
• JOMAA H, WIESNER J, SANDERBRAND S et al: Inhibitors of the nonmevalonate pathway of isoprenoid biosynthesis as antimalarial drugs. Science (1999) 285(5433):1573–1576.
   PubMed Web of Science ®Google Scholar
• RIDLEY RG: Planting the seeds of new antimalarial drugs. Science (1999) 285(5433):1502–1503.
   PubMedGoogle Scholar
• BORRMANN S, ADEGNIKA AA, MATSIEGUI PB et al.: Fosmidomycin-clindamycin for Plasmodium fakiparum infections in African children. .1. Infect. Dis. (2004) 189(5):901–908.
   Google Scholar
• WIESNER J, HENSCHKER D, HUTCHINSON DB, BECK E, JOMAA H: In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob. Agents Chemother. (2002) 46(9):2889–2894.
   PubMed Web of Science ®Google Scholar
• RIECKMANN KH: The in vitro activity of experimental antimalarial compounds against strains of I? fakiparum with varying degrees of sensitivity to pyrimethamine and chloroquine. Chemother. Malaria Resist. Antimalarials (1973) 529:58.
   Google Scholar
• BASCO LK, ELDIN DE PECOULAS P, WILSON CM, LE BRAS J, MAZABRAUD A: Point mutations in the dihydrofolate reductase-thymidylate synthase gene and pyrimethamine and cycloguanil resistance in Plasmodium fakiparum. MM. Biochem. Parasitol (1995) 69(1):135–138.
   PubMedGoogle Scholar
• COWMAN AF, MORRY MJ, BIGGS BA, CROSS GA, FOOTE SJ: Amino acid changes linked to pyrimethamine resistance in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falciparum. Proc Natl. Acad. Sci. USA (1988) 85(23):9109–9113.
   PubMed Web of Science ®Google Scholar
• FOOTE SJ, GALATIS D, COWMAN AF: Amino acids in the dihydrofolate reductase-thymidylate synthase gene of Plasmodium falcipamm involved in cycloguanil resistance differ from those involved in pyrimethamine resistance. Proc. Natl. Acad. Sci. USA (1990) 87(8):3014–3017.
   PubMed Web of Science ®Google Scholar
• PETERSON DS, MILHOUS WK, WELLEMS TE: Molecular basis of differential resistance to cycloguanil and pyrimethamine in Plasmodium fakiparum malaria. Proc. Natl. Acad. Sci. USA (1990) 87(8):3018–3022.
   PubMedGoogle Scholar
• PETERSON DS, WALLIKER D, WELLEMS TE: Evidence that a point mutation in dihydrofolate reductase-thymidylate synthase confers resistance to pyrimethamine in falciparum malaria. Proc. Natl. Acad. Sci. USA (1988) 85(23):9114–9118.
   PubMed Web of Science ®Google Scholar
• SIRAWARAPORN W, SATHITKUL T, SIRAWARAPORN R, YUTHAVONG Y, SANTI DV: Antifolate-resistant mutants of Plasmodium falciparum dihydrofolate reductase. Proc. Natl. Acad. Sci. USA (1997) 94(4):1124–1129.
   PubMed Web of Science ®Google Scholar
• RASTELLI G, SIRAWARAPORN W, SOMPORNPISUT P et al.: Interaction of pyrimethamine, cycloguanil, WR-99210 and their analogues with Plasmodium falcipamm dihydrofolate reductase: structural basis of antifolate resistance. Bioorg. Med. Chem. (2000) 8(5):1117–1128.
   PubMed Web of Science ®Google Scholar
• FISHMAN M, CRUCKSHANK PA: Febrifugine antimalarial agents. 1. pyridine analogs of febrifugine. Med. Chem. (1970) 13(1):155–156.
   Google Scholar
• TAKAYA Y, TASAKA H, CHIBA T et al.:New type of febrifugine analogues, bearing a quinolizidine moiety, show potent antimalarial activity against Plasmodium malaria parasite. J. Med. Chem. (1999) 42 (16):3163–3166.
   PubMed Web of Science ®Google Scholar
• SOLAJA BA, TERZIC N, POCSFALVI G: Mixed steroidal 1,2,4,5-tetraoxanes: antimalarial and antimycobacterial activity. Med. Chem. 45(16):3331–3336.
   Google Scholar